New FDA Guidance Aims to Boost Access to Opioid-Reversal Drug
Under new guidance, harm reduction programs distributing naloxone will be exempt from certain federal requirements in an effort to increase access to the opioid antidote.
Medscape Medical News
source https://www.medscape.com/viewarticle/982472?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/982472?src=rss
Comments
Post a Comment